SCHEMBL7553197

SCHEMBL7553197

Fc1ccc(Cl)c2ccccc12

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 4/20 0.68
CYP1A2 P05177 3/20 0.68
KMT2A Q03164 1/20 0.43
ATM Q13315 1/20 0.43
NR4A2 P43354 1/20 0.41
TSHR P16473 4/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
ALDH1A1 P00352 1/20 0.39
LMNA P02545 2/20 0.38
HPRT1 P00492 1/20 0.37
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
DAO P14920 1/20 0.35
PHOSPHO1 Q8TCT1 1/20 0.35
POLB P06746 1/20 0.34
EGFR P00533 2/20 0.34
KDM4E B2RXH2 2/20 0.33
MPI P34949 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29915195 1.00 CYP2A6 (0.68) CYP2A6CYP1A2KMT2AATMNR4A2
SCHEMBL29494605 0.83 CYP2A6 (1.00) CYP2A6CYP1A2KMT2AATMNR4A2
SCHEMBL30366540 0.83 HPRT1 (0.46) CYP2A6CYP1A2TSHRALDH1A1LMNA
SCHEMBL6562728 0.83 HPRT1 (0.46) CYP2A6CYP1A2TSHRALDH1A1LMNA
SCHEMBL2473555 0.83 CYP2A6 (1.00) CYP2A6CYP1A2KMT2AATMNR4A2
SCHEMBL16917822 0.75 HTR1B (0.42) CYP2A6TSHRALDH1A1LMNAHPRT1
Benzene SCHEMBL28735904 0.70 CYP2A6 (0.72) CYP2A6CYP1A2KMT2AATMNR4A2
Chlorobenzene SCHEMBL8843335 0.70 TSHR (0.46) CYP1A2KMT2ANR4A2TSHRNPC1
SCHEMBL2468811 0.70 CYP1A2 (1.00) CYP2A6CYP1A2KMT2AATMNR4A2
SCHEMBL29618976 0.70 CES2 (0.43) CYP2A6CYP1A2TSHRALDH1A1HPRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE37670-E1 Antiproliferative and neurotrophic molecules AMERICAN BIOGENETICS INC. 2002-04-23 US claimed
US-20020013367-A1 Antiproliferative and neurotrophic molecules NAU HEINZ (DE) 2002-01-31 US claimed
US-6300373-B1 CONTACTING NEURONAL CELLS WITH A NEUROTROPHIC AMOUNT CARBOXYLIC ACID DERIVATIVE FOR PROVIDING NEUROTROPHIC ACTIVITY AMERICAN BIOGENETIC SCIENCES, INC. 2001-10-09 US claimed
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors MIRATI THERAPEUTICS INC (US) 2024-06-27 US disclosed
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors MIRATI THERAPEUTICS INC (US) 2024-06-27 US disclosed
US-20240215277-A1 ORGANIC ELECTROLUMINESCENT DEVICE MERCK PATENT GMBH (DE) 2024-06-27 US disclosed
EP-4304720-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2024-01-17 EP disclosed
WO-2022192745-A1 MTA-COOPERATIVE PRMT5 INHIBITORS Mirati Therapeutics, Inc. (US) 2022-09-15 WO disclosed
CN-1150166-C CB2 receptor agonist compounds ��ŵ�Ѻϳ�ʵ���� 2004-05-19 CN disclosed
WO-2001020995-A9 COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF UNIV WASHINGTON (US) 2002-11-14 WO disclosed
US-RE37670-E1 Antiproliferative and neurotrophic molecules AMERICAN BIOGENETICS INC. 2002-04-23 US disclosed
US-20020013367-A1 Antiproliferative and neurotrophic molecules NAU HEINZ (DE) 2002-01-31 US disclosed
US-6300373-B1 CONTACTING NEURONAL CELLS WITH A NEUROTROPHIC AMOUNT CARBOXYLIC ACID DERIVATIVE FOR PROVIDING NEUROTROPHIC ACTIVITY AMERICAN BIOGENETIC SCIENCES, INC. 2001-10-09 US disclosed
US-6274624-B1 COMPOUNDS SUCH AS 2-N-PENTYL-4-PENTYNOIC ACID AS ANTIMITOTIC AGENTS AMERICAN BIOGENETIC SCIENCES INC. 2001-08-14 US disclosed
WO-2001020995-A1 COMPOUNDS DIRECTED AGAINST PILUS BIOGENESIS AND ACTIVITY IN PATHOGENIC BACTERIA; METHODS AND COMPOSITIONS FOR SYNTHESIS THEREOF WASHINGTON UNIVERSITY (US) 2001-03-29 WO disclosed
CN-1192732-A CB2 receptor agonist compounds SANOFI SA (FR) 1998-09-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208912-A1 MTA-Cooperative PRMT5 Inhibitors PRMT1, PRMT5, PRMT6 CYP2A6 4345/4885CYP1A2 4055/4885KMT2A 165/4885
US-20020013367-A1 Antiproliferative and neurotrophic molecules BDNF, NGF, NTRK2 CYP2A6 4754/4885CYP1A2 4854/4885KMT2A 3259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.